Cargando…

KEYNOTE-407: new hope for the treatment of lung squamous cell carcinoma

Detalles Bibliográficos
Autores principales:	Zhao, Xinmin, Wang, Jialei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225143/ https://www.ncbi.nlm.nih.gov/pubmed/32420086 http://dx.doi.org/10.21037/tlcr.2020.03.12

Ejemplares similares

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study
por: Gómez-Randulfe, Igor, et al.
Publicado: (2023)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407
por: Sugawara, Shunichi, et al.
Publicado: (2023)

The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer
por: Wang, Yanye, et al.
Publicado: (2020)

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
por: Novello, Silvia, et al.
Publicado: (2023)

New first-line treatment strategies for advanced lung squamous cell carcinoma
por: Cai, Xiuyu, et al.
Publicado: (2020)

Translating KEYNOTE-048 into practice recommendations for head and neck cancer
por: Szturz, Petr, et al.
Publicado: (2020)

Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
por: Sano, Daisuke, et al.
Publicado: (2023)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
por: Pai, Sara I., et al.
Publicado: (2019)

Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
por: de Silva, Madhawa, et al.
Publicado: (2020)

Hope for new antibiotics for syphilis treatment
por: Stamm, Lola V.
Publicado: (2021)

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020)

Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?
por: Pichler, Renate, et al.
Publicado: (2019)

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
por: Borcoman, Edith, et al.
Publicado: (2020)

Intracranial Glioblastomas: New Hope for an Effective Treatment
por: Cooper, Arthur J.L.
Publicado: (2015)

Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?
por: Shing, Kit, et al.
Publicado: (2020)

Biomarkers for Treatment Monitoring in Tuberculosis: A New Hope
por: Babu, Subash
Publicado: (2017)

New hope for haplotype mapping
por: Bell, John I
Publicado: (2003)

Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
por: Li, Fengtan, et al.
Publicado: (2021)

Hypoxia therapy--a new hope for the treatment of mitochondrial dysfunctions
por: Huang, Jun-long, et al.
Publicado: (2016)

The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

New ways and new hopes for IGR development
por: Jindra, Marek
Publicado: (2021)

Keynotes
Publicado: (2023)

New Hopes for Treatment of Alzheimer’s Disease
por: Akhondzadeh, Shahin
Publicado: ( 201)

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
por: Russo, Alessandro, et al.
Publicado: (2019)

Immunotherapy in Thoracic Malignancies: New Treatment and New Hope
por: Melosky, Barbara
Publicado: (2022)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

New targets, new hopes
por: Strijbos, M., et al.
Publicado: (2022)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

Inhaled aptamer therapy: A hopeful therapy for lung disease
por: Martin, M. Elena
Publicado: (2023)

KEYNOTE-564: Adjuvant immunotherapy for renal cell carcinoma
por: Pandey, Abhishek
Publicado: (2022)

Keynote Address
por: Zinsou, Lionel
Publicado: (2019)

Keynote Address
por: Cherkaoui El Moursli, Rajaa
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n2e9i8homd23jk5oaqdcam0260